Stock Financial Ratios

NVLN / NOVELION THERAPEUTICS INC. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.27
Volume29,500.00
Market Cap ($M)130.82
Enterprise Value ($M)-3.93
Book Value ($M)135.79
Book Value / Share7.32
Price / Book1.96
NCAV ($M)-178.86
NCAV / Share32.08
Price / NCAV-0.42
Income Statement (mra) ($M)
Revenue13.57
EBITDA-36.71
Net Income-52.87
Balance Sheet (mrq) ($M)
Cash & Equivalents70.50
Cash / Share6.25
Assets0.00
Liabilities370.05
Quick Ratio0.77
Current Ratio1.40
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.39
Return on Assets (ROA)-0.11
Return on Equity (ROE)-0.39
Identifiers and Descriptors
CUSIP746927102
Central Index Key (CIK)827809
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
67001K103
67001K952
67001K202
67001K902
Share Statistics
Common Shares Outstanding18,558,072
Common Stock Shares Outstanding18,530,323
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Liabilities Current Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Assets Current Per Share7.05
Current Portion Of Long Term Debt Per Share0.00
Accounts Receivable Per Share0.78
Property Plant And Equipment Per Share0.00
Cash Per Share6.25
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Equity Per Share2.06
Liabilities Per Share32.79
Accumulated Depreciation And Depletion Per Share0.00
Cash And Equivalents Per Share3.80
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Inventory Raw Materials Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Inventory Per Share0.85
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00

Related News Stories

BRIEF-Novelion Says U.S. District Court Judge Sentenced Unit Aegerion Pharmaceuticals

2018-01-30 reuters
* NOVELION THERAPEUTICS INC - ANNOUNCED THAT A U.S. DISTRICT COURT JUDGE HAS SENTENCED NOVELION SUBSIDIARY AEGERION PHARMACEUTICALS (4-0)

BRIEF-Novelion Therapeutics Announces Cost Reduction Plans, Capital Structure Review

2018-01-24 reuters
* NOVELION THERAPEUTICS -ANNOUNCED COST REDUCTION PLANS AS IT MANAGES CASH RESOURCES, EFFECTS OF DELAY & UNCERTAINTY OF SETTLEMENT OF UNIT WITH DOJ, SEC (4-0)

Drug charity sues U.S. over restrictions on donor communications

2018-01-09 reuters
BOSTON (Reuters) - A U.S. charity offering assistance to patients on out-of-pocket drug costs on Monday sued the federal government over restrictions on its ability to communicate with drugmakers who donate to it. (9-1)

Novelion unit asks U.S. judge to approve plea deal, cites money woes

2017-12-22 reuters
BOSTON, Dec 22 (Reuters) - Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case’s uncertainty. (8-0)

BRIEF-Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice

2017-11-21 reuters
* Novelion Therapeutics - ‍district judge William Young rejected Aegerion Pharmaceuticals’ amended criminal plea agreement which was negotiated with U.S. DOJ (8-0)

CUSIP: 746927102